CD79b Targeted Therapies
1 drugsAbout CD79b
CD79b, or B cell antigen receptor complex-associated protein beta chain, is essential to the B cell receptor (BCR) complex. It regulates B cell activation, proliferation, and differentiation through the BCR signaling pathway.
CD79b is a compelling therapeutic target due to its functional importance in B cell activity. Currently, there is no genetic evidence directly linking CD79b to specific diseases.
POLIVY (polatuzumab vedotin) is the only FDA-approved drug targeting CD79b. It is an antibody-drug conjugate (ADC) developed by Roche, with approvals in 2019 for three indications.
Top CD79b Drugs
Roche is the only company with an approved drug targeting CD79b.
Low competition may present an opportunity, but also indicates potential challenges in target validation or market size.
CD79b Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets CD79b, using adc modality.
The ADC-only landscape suggests an opportunity to explore alternative modalities like small molecules or bispecific antibodies.
CD79b Clinical Trials 84 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on CD79b. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 29 | 11 | 3 | 15 | 79% |
| Phase 2 | 46 | 2 | 3 | 41 | 40% |
| Phase 3 | 8 | 3 | 1 | 4 | 75% |
| Phase 4 | 1 | 0 | 0 | 1 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
CD79b Drug Approval Timeline (2019 - 2019)
Previously untreated diffuse large B-cell lymphoma (DLBCL...
The first and most recent drug approval for CD79b was POLIVY in 2019.
The recent approval and lack of subsequent drugs suggest the target is still emerging, with potential for further development.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 51 (9 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on CD79b. A trial counts if an approved drug acting on CD79b is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.